Syros Pharmaceuticals (SYRS) Stock Rating Lowered by Zacks Investment Research
Syros Pharmaceuticals (NASDAQ:SYRS) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Saturday. They presently have a $12.00 target price on the stock. Zacks Investment Research‘s price objective suggests a potential upside of 11.11% from the company’s current price.
According to Zacks, “Syros Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on treatments for cancer and immune-mediated diseases as well as building a pipeline of gene control medicines. The company’s product pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia and relapsed high-risk myelodysplastic syndrome and SY-1365, a selective CDK7 inhibitor for acute leukemia which is in preclinical stage. Syros Pharmaceuticals, Inc. is based in Cambridge, Massachusetts. “
Several other brokerages have also recently commented on SYRS. JMP Securities raised shares of Syros Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $33.00 price target on the stock in a research report on Thursday, September 28th. Cowen reissued a “buy” rating on shares of Syros Pharmaceuticals in a research report on Monday, December 11th. Oppenheimer set a $28.00 price target on shares of Syros Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, January 8th. ValuEngine cut shares of Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, September 22nd. Finally, Roth Capital initiated coverage on shares of Syros Pharmaceuticals in a research report on Monday, October 23rd. They set a “neutral” rating and a $15.00 price target on the stock. One analyst has rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $22.36.
Syros Pharmaceuticals (NASDAQ:SYRS) last issued its quarterly earnings results on Wednesday, November 8th. The company reported ($0.53) EPS for the quarter, hitting the consensus estimate of ($0.53). equities analysts anticipate that Syros Pharmaceuticals will post -2.12 EPS for the current year.
In other news, insider Jeremy P. Springhorn bought 15,000 shares of the company’s stock in a transaction dated Friday, December 15th. The shares were bought at an average cost of $9.08 per share, with a total value of $136,200.00. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Srinivas Akkaraju bought 109,774 shares of the company’s stock in a transaction dated Thursday, December 14th. The stock was purchased at an average cost of $9.03 per share, for a total transaction of $991,259.22. The disclosure for this purchase can be found here. 33.60% of the stock is currently owned by corporate insiders.
Several hedge funds have recently modified their holdings of the company. FMR LLC raised its holdings in shares of Syros Pharmaceuticals by 11.9% in the 2nd quarter. FMR LLC now owns 3,926,998 shares of the company’s stock valued at $63,185,000 after purchasing an additional 418,061 shares during the period. Redmile Group LLC grew its stake in Syros Pharmaceuticals by 2.2% in the 2nd quarter. Redmile Group LLC now owns 973,260 shares of the company’s stock valued at $15,660,000 after buying an additional 20,520 shares during the last quarter. Vanguard Group Inc. grew its stake in Syros Pharmaceuticals by 189.6% in the 2nd quarter. Vanguard Group Inc. now owns 382,603 shares of the company’s stock valued at $6,156,000 after buying an additional 250,507 shares during the last quarter. State Street Corp grew its stake in Syros Pharmaceuticals by 176.7% in the 2nd quarter. State Street Corp now owns 169,497 shares of the company’s stock valued at $2,728,000 after buying an additional 108,250 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its stake in Syros Pharmaceuticals by 15.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 126,530 shares of the company’s stock valued at $1,926,000 after buying an additional 17,330 shares during the last quarter. 57.96% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION WARNING: This news story was first published by Watch List News and is owned by of Watch List News. If you are accessing this news story on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be accessed at https://www.watchlistnews.com/syros-pharmaceuticals-syrs-stock-rating-lowered-by-zacks-investment-research/1817408.html.
About Syros Pharmaceuticals
Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.